🔎 Trials Near Me

Home › Sakit na Sjögren › Arizona

Pag-aaral pangklinika para sa Sakit na Sjögren sa Arizona

5 pag-aaral para sa Sakit na Sjögren ang naghahanap ng mga kalahok sa mga site sa Arizona.

Mga Lungsod sa Arizona

Opisyal na teksto ng pag-aaral (English)

A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

  • Arizona Arthritis and Rheumatology Associates PLLC, Avondale
Nagre-recruitPhase 2
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT07737743

Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

  • Sun Valley Arthritis Center Ltd, Peoria
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT07621809

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

  • Arizona Arthritis & Rheumatology Associates P.C., Chandler
  • Arizona Arthritis & Rheumatology Associates P.C., Flagstaff
  • Arizona Arthritis & Rheumatology Associates, PLLC, Glendale
  • at 2 pa
Nagre-recruitPhase 3
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Okt 19, 2026 · NCT07404865

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

  • Artiva Investigational Site Phoenix, Phoenix
  • Artiva Investigational Site Tucson, Tucson
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 31, 2026 · NCT06991114

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

  • Arizona Arthritis & Rheumatology Associates - Avondale, Avondale
  • Arizona Arthritis and Rheumatology Associates - Flagstaff - 399 S Malpais Ln, Flagstaff
  • Arizona Arthritis and Rheumatology Associates - Gilbert - 3645 S Rome St, Gilbert
  • at 2 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 28, 2026 · NCT06747949

Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.